{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:58:27Z","timestamp":1790398707656,"version":"4.1.0"},"reference-count":28,"publisher":"BMJ","issue":"10","funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2017,8,17]]},"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This phase II, randomised, double-blind, placebo-controlled clinical trial was designed to evaluate the efficacy and safety of PF-00547659, a fully human monoclonal antibody that binds to human mucosal addressin cell adhesion molecule (MAdCAM) to selectively reduce lymphocyte homing to the intestinal tract, in patients with moderate-to-severe Crohn\u2019s disease (CD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Eligible adults were aged 18\u201375 years, with active moderate-to-severe CD (Crohn\u2019s Disease Activity Index (CDAI) 220\u2013450), a history of failure or intolerance to antitumour necrosis factor and\/or immunosuppressive agents, high-sensitivity C reactive protein &gt;3.0\u2009mg\/L and ulcers on colonoscopy. Patients were randomised to PF-00547659 22.5\u2009mg, 75\u2009mg or 225\u2009mg or placebo. The primary endpoint was CDAI 70-point decrease from baseline (CDAI-70) at week 8 or 12.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In all, 265 patients were eligible for study entry. Although CDAI-70 response was not significantly different with placebo versus PF-00547659 treatment at weeks 8 or 12, remission rate was greater in patients with higher baseline C reactive protein (&gt;5\u2009mg\/L vs &gt;18.8\u2009mg\/L, respectively). Soluble MAdCAM decreased significantly from baseline to week 2 in a dose-related manner and remained low during the study in PF-00547659-treated patients. Circulating \u03b2<jats:sub>7<\/jats:sub>+ CD4+ central memory T-lymphocytes increased at weeks 8 and 12 with PF-00547659 treatment. No safety signal was seen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Clinical endpoint differences between PF-00547659 and placebo did not reach statistical significance in patients with moderate-to-severe CD. PF-00547659 was pharmacologically active, as shown by a sustained dose-related decrease in soluble MAdCAM and a dose-related increase in circulating \u03b2<jats:sub>7<\/jats:sub>+ central memory T cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01276509\" specific-use=\"clinicaltrial results\">NCT01276509<\/jats:ext-link>; Results.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/gutjnl-2016-313457","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T10:27:12Z","timestamp":1537871232000},"page":"1824-1835","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":97,"title":["Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn\u2019s disease: report of the OPERA study"],"prefix":"10.1136","volume":"67","clinical-trial-number":[{"clinical-trial-number":"nct01276509","registry":"10.18810\/clinical-trials-gov","type":"results"}],"author":[{"given":"William J","family":"Sandborn","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dino","family":"Tarabar","sequence":"additional","affiliation":[{"name":"Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Louis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital CHU of Liege, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Klopocka","sequence":"additional","affiliation":[{"name":"Department of Vascular Diseases and Internal Medicine, Nicolaus Copernicus University, Toru\u0144, Collegium Medicum in Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Klaus","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universitatsklinikum Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Medical University of Vienna, Vienna, Austria"},{"name":"Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"H\u00e9buterne","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universit\u00e9 de Nice Sophia Antipolis, H\u00f4pital de l\u2019Archet, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Il","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology, Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyaprakash","family":"Nayak","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa S","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cataldi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J","family":"Gorelick","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Hassan-Zahraee","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Clare","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert R","family":"D\u2019Haens","sequence":"additional","affiliation":[{"name":"IBD Unit, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"key":"2025090713005850000_67.10.1824.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60026-9"},{"key":"2025090713005850000_67.10.1824.2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.06.070"},{"key":"2025090713005850000_67.10.1824.3","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.168"},{"key":"2025090713005850000_67.10.1824.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.03.014"},{"key":"2025090713005850000_67.10.1824.5","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2025090713005850000_67.10.1824.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"2025090713005850000_67.10.1824.7","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00159"},{"key":"2025090713005850000_67.10.1824.8","doi-asserted-by":"publisher","DOI":"10.1038\/331041a0"},{"key":"2025090713005850000_67.10.1824.9","doi-asserted-by":"publisher","DOI":"10.1038\/337179a0"},{"key":"2025090713005850000_67.10.1824.10","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am J Pathol"},{"key":"2025090713005850000_67.10.1824.11","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.090437"},{"key":"2025090713005850000_67.10.1824.12","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025090713005850000_67.10.1824.13","doi-asserted-by":"crossref","unstructured":"Colombel JF , Sands BE , Rutgeerts P , et al . The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease. Gut 2016.","DOI":"10.1136\/gutjnl-2015-311079"},{"key":"2025090713005850000_67.10.1824.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00137.x"},{"key":"2025090713005850000_67.10.1824.15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"2025090713005850000_67.10.1824.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(04)01878-4"},{"key":"2025090713005850000_67.10.1824.17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cyto.a.22351","article-title":"From\u00a0\u2018truly na\u00efve\u2019 to \u2018exhausted senescent\u2019\u00a0T cells: when markers predict functionality","volume":"85","author":"Larbi","year":"2014","journal-title":"Cytometry Part A"},{"key":"2025090713005850000_67.10.1824.18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.01.024"},{"key":"2025090713005850000_67.10.1824.19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.06.064"},{"key":"2025090713005850000_67.10.1824.20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.024"},{"key":"2025090713005850000_67.10.1824.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.04.031"},{"key":"2025090713005850000_67.10.1824.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492"},{"key":"2025090713005850000_67.10.1824.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203572"},{"key":"2025090713005850000_67.10.1824.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020732"},{"key":"2025090713005850000_67.10.1824.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.06.007"},{"key":"2025090713005850000_67.10.1824.26","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.03.025"},{"key":"2025090713005850000_67.10.1824.27","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.226548"},{"key":"2025090713005850000_67.10.1824.28","unstructured":"D\u2019Haens G , Vermeire S , Vogelsang H , et al . Central nervous system immune surveillance and circulating \u03927+ CD4 T cells under anti-madcam-1 antibody treatment for Crohn\u2019s disease: report of the TOSCA study. Gut 2017."}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2016-313457","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T20:01:06Z","timestamp":1757275266000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2016-313457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,9,7]]},"published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1136\/gutjnl-2016-313457"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2016-313457","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]}}}